Finanzen von Aptevo Therapeutics Inc (APVO)APVOAptevo Therapeutics Inc

Evaluating the bottom line, Aptevo Therapeutics Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -446.89%, provide a clear picture of how effectively APVO converts its operational activities into shareholder value.

In the context of the broader market, APVO competes directly with industry leaders such as HCWB and VIVS. With a market capitalization of $2.24M, it holds a significant position in the sector. When comparing efficiency, APVO's gross margin of N/A stands against HCWB's -69.25% and VIVS's 100.00%. Such benchmarking helps identify whether Aptevo Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Aptevo Therapeutics has reported a total revenue of $0.00 for several quarters, with a net income loss of -$6,794,000 in the most recent quarter. The company has a forward P/E of 3.8895, indicating potential undervaluation, but this is overshadowed by its negative earnings and cash flow.